{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:59:51Z","timestamp":1753891191244,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Chemotherapy regimens containing rituximab (RTX) have been extensively used to treat diffuse large B cell lymphoma (DLBCL). However, data looking at long-term safety of DLBCL patients with hepatitis B-related cirrhosis are still lacking. This study aims to report the safety and outcomes of RTX administration in DLBCL patients with hepatitis B-related cirrhosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective case series was designed and implemented, using data from January 1, 2011 to December 31, 2020. Consecutive patients who were diagnosed with DLBCL and hepatitis B-related cirrhosis receiving RTX treatment were included. The primary outcomes included HBV reactivation, hepatitis flares or abnormal liver function. Survival status, the secondary outcome measure, was observed until death, loss to follow-up, or the end of follow-up, whichever occurred first.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 8 DLBCL patients combined with hepatitis B-related cirrhosis were included in this study [4 men; median age 62.5 years (range, 44\u201377 years); median RTX-containing regimen course 5 (range, 2\u201311)]. Of them, 6 patients had current HBV infection with HBsAg-positive and anti-HBc-positive, whereas 2 patients had previously resolved HBV infection with HBsAg-negative and anti-HBc-positive. The HBV reactivation was observed in only one patient, who received 11 courses of RTX-containing immunochemotherapies within 15 months. No hepatitis flares or abnormal liver function occurred in any patients included. All patients received standardized antiviral therapy for a lifelong time. Of 8 patients included, 3 patients died, and 1 patient was lost to follow-up, and the median overall survival among patients was 39 months (range, 7\u201382 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings provide support for the concept that, on the premise of standardized and valid management strategy, RTX containing regimens may be a safe option for use as the treatment of DLBCL patients combined with hepatitis B-related cirrhosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.890339","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T05:32:20Z","timestamp":1654061540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series"],"prefix":"10.3389","volume":"9","author":[{"given":"Zaiwei","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","article-title":"Non-hodgkin lymphoma: an update","volume":"5","author":"Hennessy","year":"2004","journal-title":"Lancet Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology."},{"key":"B5","unstructured":"2021"},{"key":"B6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4103\/0366-6999.237401","article-title":"Three-year Follow-up on the safety and effectiveness of rituximab plus chemotherapy as first -line treatment of diffuse large b-cell lymphoma and follicular lymphoma in real-world clinical settings in China: a prospective, multicenter, noninterventional study","volume":"131","author":"Wu","year":"2018","journal-title":"Chin Med J (Eng)."},{"key":"B8","unstructured":"2021"},{"key":"B9","unstructured":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","article-title":"Global liver disease burdens and research trends: analysis from a Chinese perspective","volume":"71","author":"Xiao","year":"2019","journal-title":"J Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12328-009-0100-1","article-title":"Current treatment for chronic hepatitis B in Japan","volume":"2","author":"Ohishi","year":"2009","journal-title":"Clin J Gastroenterol."},{"key":"B15","unstructured":""},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000943","article-title":"Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy","volume-title":"J Immunother Cancer.","author":"Ziogas","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.21037\/atm.2016.12.25","article-title":"Optimizing antiviral agents for hepatitis B management in malignant lymphomas","volume":"5","author":"Ozoya","year":"2017","journal-title":"Ann Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1016\/j.ejca.2013.07.006","article-title":"Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group","volume":"49","author":"Kim","year":"2013","journal-title":"Eur J Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B Reactivation in patients with previous hepatitis B virus exposure undergoing Rituximab\u2014containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol."},{"key":"B21","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume-title":"Blood.","author":"Steven H Swerdlow","year":"2016"},{"key":"B22","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2004.11.015","article-title":"Assessment of the prognosis of cirrhosis: child\u2013pugh versus MELD","volume":"42","author":"Durand","year":"2005","journal-title":"J Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"B26","article-title":"Chinese society of lymphoma, Chinese anti-cancer association, Chinese society of hematology, Chinese Medical association. the consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy","volume-title":"Chin J Hematol.","author":"Zhonghua","year":"2021"},{"key":"B27","unstructured":"2017"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: asco provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(10)70167-4","article-title":"Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study","volume":"11","author":"Engels","year":"2010","journal-title":"Lancet Oncol."},{"key":"B30","first-page":"22167","article-title":"Association of risk of non-Hodgkin's lymphoma with hepatitis B virus infection: a meta-analysis","volume":"8","author":"Qi","year":"2015","journal-title":"Int J Clin Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/apt.15132","article-title":"Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma","volume":"49","author":"Su","year":"2019","journal-title":"Aliment Pharm Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.clml.2013.07.002","article-title":"Bendamustine and rituximab for indolent B-Cell non-hodgkin lymphoma in patients with compensated hepatitis c cirrhosis: a case series","volume":"13","author":"Parker","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B33","doi-asserted-by":"publisher","first-page":"685706","DOI":"10.3389\/fonc.2021.685706","article-title":"Reactivation during the treatment of non-hodgkin lymphoma and management strategies","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14787210.2016.1220831","article-title":"Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis","volume":"14","author":"Zheng","year":"2016","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2169\/internalmedicine.5678-20","article-title":"Hepatitis B virus reactivation 55 months following chemotherapy including rituximab and autologous peripheral blood stem cell transplantation for malignant lymphoma","volume":"60","author":"Hara","year":"2021","journal-title":"Internal Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.15932\/j.0253-9713.2007.09.025","article-title":"Hepatic dysfunction in asymptomatic carrier of HBV after rituximab combined with chemotherapy in non-Hodgkin lymphoma patients (report of 5 cases)","volume":"29","author":"Jing","year":"2007","journal-title":"Beijing Med J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.890339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T05:32:28Z","timestamp":1654061548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.890339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":39,"alternative-id":["10.3389\/fmed.2022.890339"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.890339","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"article-number":"890339"}}